Genomic mutation testing is critical to therapeutic selection and management of patients with colorectal cancer.
In a new multicentre study, researchers compared a new cartridge-based laboratory testing device called the IdyllaTM automated system (Biocartis) to current standard-of-care testing methods.
They found that average turnaround time for test results could be cut by more than 65% from 15 days to 5 days, with some results available in a single day.
The significant decrease in wait time means patients can begin appropriate treatments for colorectal cancer much sooner.
The simplicity and ease of use of the new technology compared with other molecular techniques also makes it suitable for integration into clinical laboratories of any size, including those that may not have much molecular expertise.
“This is the first such study to address turnaround time for when the oncologist receives clinically actionable results from the lab,” says lead author Gregory J. Tsongalis, PhD, of Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center, USA.
“Getting results to our oncologists in a timely fashion allows them to be better prepared in the selection of a therapeutic management strategy.”
Results of the study, “Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer,” are newly published online in the American Journal of Clinical Pathology.
Also significant in this study is the participation of 20 laboratories of different types and sizes – not just larger academic centre labs – throughout the United States and Puerto Rico, with an accrual of almost 800 colorectal cancer tissue samples to measure.
In collecting the data, the study also addressed the use of minimal tissue from the patient sample.
“One of the study sites included several 1-mm tissue biopsy samples, showing that even smaller tissue-based specimens can be successfully analysed by Idylla,” notes Tsongalis.
“Our results are in line with findings of other studies showing successful analyses using very small tissue amounts, including those deemed too small for standard molecular testing methods.”
Next steps include looking at strategies to integrate the new platform into regular laboratory processes. “We already use something similar for our melanoma patients,” notes Tsongalis.
As the majority of care of cancer patients in the United States is provided in smaller medical facilities, this user-friendly system would allow those institutions to offer the most clinically actionable testing at their own hospitals with minimal hands-on time for testing and rapid result reporting.